mavacamten sold brand name camzyos medication used treat obstructive hypertrophic mavacamten smallmolecule allosteric cardiac myosin developed myokardia subsidiary bristol myers clinical studies mavacamten demonstrated significant efficacy reducing cardiac muscle contractility targeting sarcomere hypercontractility one characteristics hypertrophic cardiomyopathy inhibits excessive myosin actin crossbridge formation shifting overall myosin population towards energysparing recruitable superrelaxed mavacamten approved medical use united states april us food drug administration fda considers firstinclass mavacamten indicated treatment adults symptomatic new york heart association class iiiii obstructive hypertrophic cardiomyopathy improve functional capacity us prescribing information mavacamten contains boxed warning regarding heart failure mavacamten reduces lvef cause heart failure due systolic mavacamten granted orphan drug designation us food drug administration april committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product camzyos intended treatment symptomatic obstructive hypertrophic cardiomyopathy applicant medicinal product bristolmyers squibb pharma june european commission approved mavacamten approved use south mavacamten international nonproprietary name httpsenwikipediaorgwikimavacamten